HistoSonics Wins Taiwan Approval for Tumor-Destroying Ultrasound, Expands in Asia
▼ Summary
– HistoSonics received regulatory approval from Taiwan’s Food and Drug Administration for its Edison Histotripsy System on 18 May.
– The system is a non-invasive cancer treatment device that uses focused ultrasound to destroy tumors without cutting, radiation, or thermal damage.
– The TFDA authorization marks a significant step in the company’s expansion into Asia.
– Taiwan is added to the list of regions where the device is approved for use.
HistoSonics has secured regulatory clearance from Taiwan’s Food and Drug Administration (TFDA) for its Edison Histotripsy System, a breakthrough non-invasive cancer treatment that employs focused ultrasound to destroy tumors without incisions, radiation, or heat-based damage. Announced on May 18, this approval represents a pivotal milestone in the company’s push into Asian markets, adding Taiwan to its growing list of authorized territories.
The Edison system uses a technology called histotripsy, which mechanically breaks down targeted tissue at a cellular level using precisely controlled ultrasound waves. Unlike conventional therapies such as surgery or ablation, this method spares surrounding healthy tissue and avoids the side effects often associated with thermal or radiation-based approaches. The device has already received approvals in other regions, and its entry into Taiwan signals increasing global confidence in ultrasound-based oncology.
For HistoSonics, the TFDA nod opens the door to one of Asia’s most advanced healthcare systems. Taiwan’s well-established medical infrastructure and proactive regulatory environment make it a strategic beachhead for broader regional adoption. The company plans to introduce the system to Taiwanese hospitals and clinics, offering patients an alternative that reduces recovery time and procedural risks.
This expansion aligns with a broader trend toward non-invasive cancer therapies that prioritize patient quality of life. By eliminating the need for incisions or ionizing radiation, histotripsy can be performed on an outpatient basis, often with minimal discomfort. The technology is particularly promising for liver tumors, though research is underway for applications in other organs.
HistoSonics continues to pursue approvals in additional Asian countries, leveraging the TFDA clearance as a reference for other regulatory bodies. As the company scales its presence, the Edison system could become a standard tool in oncology departments across the region, reshaping how clinicians approach tumor destruction.
(Source: The Next Web)
